BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1026 related articles for article (PubMed ID: 20381492)

  • 1. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B.
    Mihm U; Sarrazin C; Herrmann E; Teuber G; von Wagner M; Kronenberger B; Zeuzem S
    Z Gastroenterol; 2003 Mar; 41(3):249-54. PubMed ID: 12664345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation.
    Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.
    Lin B; Ha NB; Liu A; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Keeffe EB; Garcia RT; Garcia G; Nguyen MH
    J Gastroenterol Hepatol; 2013 May; 28(5):855-60. PubMed ID: 23278507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
    Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
    Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.
    Martín-Carbonero L; Teixeira T; Poveda E; Plaza Z; Vispo E; González-Lahoz J; Soriano V
    AIDS; 2011 Jan; 25(1):73-9. PubMed ID: 21076274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.
    Song MJ; Song DS; Kim HY; Yoo SH; Bae SH; Choi JY; Yoon SK; Paik YH; Lee JS; Lee HW; Kim HJ
    World J Gastroenterol; 2012 Nov; 18(43):6277-83. PubMed ID: 23180949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men.
    Wu JF; Tsai WY; Hsu HY; Ni YH; Chen HL; Tsuei DJ; Chang MH
    Gastroenterology; 2010 Mar; 138(3):942-8.e1. PubMed ID: 19962986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
    Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.
    Fung J; Lai CL; Tanaka Y; Mizokami M; Yuen J; Wong DK; Yuen MF
    Am J Gastroenterol; 2009 Aug; 104(8):1940-6; quiz 1947. PubMed ID: 19455108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.